Rani Therapeutics Holdings (RANI) Depreciation & Amortization (CF) (2020 - 2026)
Rani Therapeutics Holdings (RANI) posted quarterly Depreciation & Amortization (CF) of $161000.0 for Q1 2026, down 35.86% year-over-year from $251000.0 in Q1 2025, and down 13.44% quarter-over-quarter from $186000.0 in Q4 2025.
Rani Therapeutics Holdings (RANI) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Rani Therapeutics Holdings' Depreciation & Amortization (CF) history runs 7 years deep, the most recent figure standing at $161000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 35.86% year-over-year to $161000.0; the TTM figure through Mar 2026 stood at $810000.0 (down 21.44% YoY), while the FY2025 annual figure was $900000.0, down 12.45% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $161000.0, down from $186000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $266000.0 in Q4 2024, with the low at $111000.0 in Q1 2022.
- The 5-year median for Depreciation & Amortization (CF) is $218000.0 (2023), against an average of $203470.6.
- The sharpest annual moves came in 2023 and 2026: Depreciation & Amortization (CF) jumped 69.37% in 2023, then plunged 35.86% in 2026.
- Rani Therapeutics Holdings' Depreciation & Amortization (CF) stood at $174000.0 in 2022, then jumped by 30.46% to $227000.0 in 2023, then advanced by 17.18% to $266000.0 in 2024, then sank by 30.08% to $186000.0 in 2025, then fell by 13.44% to $161000.0 in 2026.
- Business Quant data shows RANI's Depreciation & Amortization (CF) at $161000.0 in Q1 2026, $186000.0 in Q4 2025, and $223000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Rani Therapeutics Holdings | 163.98 Mn | 163.98 Mn | - | 152,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 152,000.00 |
| Jun 30, 2026 | 152,000.00 |
| Mar 31, 2026 | 161,000.00 |
| Mar 31, 2026 | 161,000.00 |
| Dec 31, 2025 | 186,000.00 |
| Dec 31, 2025 | 186,000.00 |
| Sep 30, 2025 | 223,000.00 |
| Sep 30, 2025 | 223,000.00 |
| Jun 30, 2025 | 240,000.00 |
| Jun 30, 2025 | 240,000.00 |
| Mar 31, 2025 | 251,000.00 |
| Mar 31, 2025 | 251,000.00 |
| Dec 31, 2024 | 266,000.00 |
| Dec 31, 2024 | 266,000.00 |
| Sep 30, 2024 | 259,000.00 |
| Sep 30, 2024 | 259,000.00 |
| Jun 30, 2024 | 255,000.00 |
| Jun 30, 2024 | 255,000.00 |
| Mar 31, 2024 | 248,000.00 |
| Mar 31, 2024 | 248,000.00 |